SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain

Sinclair, Paul B., Ryan, Sarra, Bashton, Matthew, Hollern, Shaun, Hanna, Rebecca, Case, Marian, Schwalbe, Ed, Schwab, Claire J., Cranston, Ruth E., Young, Brian D., Irving, Julie A. E., Vora, Ajay J., Moorman, Anthony V. and Harrison, Christine J. (2019) SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. Leukemia, 33 (8). pp. 1881-1894. ISSN 0887-6924

[img]
Preview
Text (Full text)
Sinclair et al - SH2B3 inactivation OA.pdf - Published Version
Available under License Creative Commons Attribution 4.0.

Download (3MB) | Preview
Official URL: https://doi.org/10.1038/s41375-019-0412-1

Abstract

In more than 30% of B-cell precursor acute lymphoblastic leukaemia (B-ALL), chromosome 21 sequence is overrepresented through aneuploidy or structural rearrangements, exemplified by intrachromosomal amplification of chromosome 21 (iAMP21). Although frequent, the mechanisms by which these abnormalities promote B-ALL remain obscure. Intriguingly, we found copy number neutral loss of heterozygosity (CN-LOH) of 12q was recurrent in iAMP21-ALL, but never observed in B-ALL without some form of chromosome 21 gain. As a consequence of CN-LOH 12q, mutations or deletions of the adaptor protein, SH2B3, were converted to homozygosity. In patients without CN-LOH 12q, bi-allelic abnormalities of SH2B3 occurred, but only in iAMP21-ALL, giving an overall incidence of 18% in this sub-type. Review of published data confirmed a tight association between overrepresentation of chromosome 21 and both CN-LOH 12q and SH2B3 abnormalities in B-ALL. Despite relatively small patient numbers, preliminary analysis linked 12q abnormalities to poor outcome in iAMP21-ALL (p = 0.03). Homology modelling of a leukaemia-associated SH2 domain mutation and in vitro analysis of patient-derived xenograft cells implicated the JAK/STAT pathway as one likely target for SH2B3 tumour suppressor activity in iAMP21-ALL.

Item Type: Article
Subjects: A300 Clinical Medicine
B900 Others in Subjects allied to Medicine
C400 Genetics
Department: Faculties > Health and Life Sciences > Applied Sciences
Depositing User: Paul Burns
Date Deposited: 01 Mar 2019 15:49
Last Modified: 31 Jul 2021 20:05
URI: http://nrl.northumbria.ac.uk/id/eprint/38263

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics